Nasdaq · Healthcare
EXELIXIS, INC. (EXEL)
As-reported financials and recent SEC filings for EXELIXIS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$2.32B
Net income
$782.6M
Net margin
33.7%
Diluted EPS
$2.78
ROE
36.2%
P/E (TTM)
18.1×
Market cap
$13.77B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B |
| Gross profit | — | — | — | — | — |
| Operating income | $872.2M | $604.6M | $170.9M | $201.5M | $286.7M |
| Net income | $782.6M | $521.3M | $207.8M | $182.3M | $231.1M |
| Diluted EPS | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-03
View on EDGAR →42026-06-03
View on EDGAR →1442026-06-01
View on EDGAR →1442026-06-01
View on EDGAR →42026-05-29
View on EDGAR →42026-05-29
View on EDGAR →42026-05-29
View on EDGAR →42026-05-29
View on EDGAR →Go deeper on EXEL
Search EXELIXIS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.